PPP1R26P2: A Drug Target / Disease Biomarker (G100133064)

Target Name: PPP1R26P2

NCBI ID: G100133064

PPP1R26P2

Other Name(s): KIAA0649P2 | protein phosphatase 1 regulatory subunit 26 pseudogene 2 | Protein phosphatase 1 regulatory subunit 26 pseudogene 2

PPP1R26P2: A Drug Target / Disease Biomarker

PPP1R26P2 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. Its primary function is to regulate the activity of the ion channels known as P-type ATP-dependent K channels (PIKAs), which are essential for the proper functioning of many cellular processes.

The research on PPP1R26P2 has primarily focused on its role in neurotransmission, particularly in the regulation of synaptic plasticity and learning. Studies have shown that alterations in PPP1R26P2 levels or activity can have a significant impact on the dynamics of neural circuits and the consequences for cognitive function.

As a drug target, PPP1R26P2 has been identified as a potential target for a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells and the disruption of normal brain function, which can result in a range of symptoms such as memory loss, movement disorders, and cognitive decline.

One of the key challenges in targeting PPP1R26P2 is its widespread distribution throughout the brain, which makes it difficult to selectively modulate its activity. However, recent studies have identified a number of potential chemical modulators of PPP1R26P2 that may be able to selectively target its activity in specific regions of the brain.

One of the most promising candidates for modulating PPP1R26P2 activity is the neurotransmitter glutamate, which is known to play a critical role in the regulation of synaptic plasticity and learning. Studies have shown that changes in glutamate levels or activity can have a profound impact on the dynamics of neural circuits, including the levels of PPP1R26P2.

In addition to its role in neurotransmission, PPP1R26P2 has also been shown to play a critical role in the regulation of ion channels and the trafficking of cells. Its expression has been observed in a variety of neural tissues, including the brain, heart, and kidneys, and its activity has been implicated in the regulation of a wide range of cellular processes.

Despite the promising potential of PPP1R26P2 as a drug target, much more research is needed to fully understand its role in neural circuits and its potential as a therapeutic target. Further studies are needed to determine the exact mechanisms by which PPP1R26P2 is involved in neural function and to explore its potential as a therapeutic agent.

In conclusion, PPP1R26P2 is a protein that has broad implications for a variety of neural processes, including neurotransmission, ion channels, and cell trafficking. Its expression has been observed in a range of neural tissues and its activity has been implicated in the regulation of many cellular processes. As a drug target, PPP1R26P2 has the potential to be a valuable tool in the development of new treatments for a variety of neurodegenerative diseases. Further research is needed to fully understand its role in neural circuits and its potential as a therapeutic agent.

Protein Name: Protein Phosphatase 1 Regulatory Subunit 26 Pseudogene 2

The "PPP1R26P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPP1R26P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets